Anti-B7-H3 ADC Combined with ATR/ATM Inhibitor for Cancer Treatment

ChangeBridge: Patent Apps - Therapeutics (A61P)

Published April 2nd, 2026

Detected April 2nd, 2026

Summary

The USPTO published patent application US20260091123A1 by Daiichi Sankyo Company Limited covering a pharmaceutical composition and method of treatment combining an anti-B7-H3 antibody-drug conjugate with an ATR inhibitor or ATM inhibitor for cancer therapy. The application claims the drug-linker conjugate structure and treatment methods. Filing date was October 9, 2025.

View original document View source feed page

What changed

Daiichi Sankyo filed USPTO patent application US20260091123A1 for a combination therapy comprising an anti-B7-H3 antibody-drug conjugate linked via thioether bond, used together with either an ATR inhibitor or ATM inhibitor for treating cancer (classified A61P 35/00). The composition claims specific CPC classifications including A61K 47/6849, A61K 31/4745, and A61K 47/65. The application names inventors Len Katsumata, Jun Hasegawa, and Chiharu Hattori.

This patent publication does not create compliance obligations for pharmaceutical companies. Companies developing similar ADC or ATR/ATM inhibitor combination therapies should review the patent claims for potential freedom-to-operate concerns. The application provides public notice of the claimed invention and its scope, which may inform R&D planning and competitive landscape assessment.

Source document (simplified)

← USPTO Patent Applications

COMBINATION OF ANTI-B7-H3 ANTIBODY-DRUG CONJUGATE AND ATR INHIBITOR OR ATM INHIBITOR

Application US20260091123A1 Kind: A1 Apr 02, 2026

Assignee

DAIICHI SANKYO COMPANY, LIMITED

Inventors

Len KATSUMATA, Jun HASEGAWA, Chiharu HATTORI

Abstract

In some aspects, an object of the present invention is to provide a pharmaceutical composition and a method of treatment comprising administering a specific anti-B7-H3 antibody-drug conjugate in combination with an ATR inhibitor or an ATM inhibitor. Solution: In some aspects, provided is a pharmaceutical composition and a method of treatment, comprising administering an antibody-drug conjugate, in which a drug-linker represented by the following formula: wherein A represents a connecting position to an anti-B7-H3 antibody, and the anti-B7-H3 antibody are conjugated via a thioether bond, in combination with an ATR inhibitor or an ATM inhibitor.